Biohaven Ltd.
corporate_fare Company Profile
Biohaven Ltd. (NYSE:BHVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for BHVN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for BHVN spans 8-K, 424B5, S-3ASR, 10-Q.
Recent high-impact activity:
- Q3 Loss Narrows to $129.3M as $430M in Partnership Cash Backstops Thin $164M Balance
- FDA Accepts Biohaven's Vyglxia NDA Resubmission, Sets Q1 2027 Goal Date and Advisory Committee
- Biohaven Licenses IgG Degrader Platform to Ono Pharma for Japan and Asia
- FDA Pauses Enrollment in Biohaven's Epilepsy Drug Trials, Shares Drop 13%
- FDA Imposes Partial Clinical Hold on Biohaven's BHV-7000 Epilepsy Program
Financial Snapshot
Short Interest & Short Volume
9.17 days to coverFINRA reported short interest of 17,899,310 shares in BHVN as of the October 15, 2026 settlement, a 6.1% decrease from the prior period — about 9.2 days to cover at its recent average daily volume. On October 30, 2026, 40.9% of BHVN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for BHVN, detected from its recent SEC filings.
Amendment to ATM Program · Significant Capacity Increase
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →